Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
Despite PGx Leads, Avastin Access Debate Not Focused on Personalized Medicine Strategies
August 25, 2010
Despite pleas of breast cancer advocates to maintain access to Avastin using gene markers to identify those most likely to benefit, there is little evidence to suggest that the drug company or regulatory experts are considering this strategy.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- NICE Agrees With FDA in Pulling Avastin's Indication for Metastatic Breast Cancer
February 23, 2011 / Pharmacogenomics Reporter - NCI's Proposed IP Policy May Hinder Personalized Medicine, Stakeholders Say
August 25, 2010 / Pharmacogenomics Reporter - UK's NICE Cites Lack of Response Markers for BMS' Yervoy as Factor in Negative Recommendation
October 19, 2011 / Pharmacogenomics Reporter - Pfizer Using Qiagen KRAS Test to Study Dacomitinib Head-to-Head Against Tarceva in NSCLC
August 17, 2011 / Pharmacogenomics Reporter - FDA's ODAC Not Swayed by Genentech's Biomarker Strategy to ID Best Responders to Avastin
June 29, 2011 / Pharmacogenomics Reporter